Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to compare the efficacy of AZD2171 [cediranib; Recentin; AstraZeneca] in combination with 5-fluorouracil, leucovorin [folinic acid], and oxaliplatin (FOLFOX) and the efficacy of bevacizumab [Avastin] in combination with FOLFOX in the second-line treatment of patients with metastatic colorectal cancer.

X
Trial Profile

A study to compare the efficacy of AZD2171 [cediranib; Recentin; AstraZeneca] in combination with 5-fluorouracil, leucovorin [folinic acid], and oxaliplatin (FOLFOX) and the efficacy of bevacizumab [Avastin] in combination with FOLFOX in the second-line treatment of patients with metastatic colorectal cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cediranib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms HORIZON-I
  • Most Recent Events

    • 22 Jan 2011 Results of an analysis investigating prognostic markers of response presented at the 2011 Gastrointestinal Cancers Symposium.
    • 17 Dec 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top